Journal of Medical Bacteriology (Mar 2023)
Zoliflodacin: A hope to treat antibiotic-resistant Neisseria gonorrhoeae
Abstract
Background: Neisseria gonorrhoeae is a gram negative diplococci which causess a sexually transmitted infection. N. gonorrhoeae is an obligate human pathogen that causes infection to the mucus-secreting epithelial cells both in male and female. In 2017, the centre of disease control and World Health Organization published the list of global priority pathogens with denting therapeutic options, including antibiotic-resistant N. gonorrhoeae. During the covid-19 pandemic, excessive use of antibiotics led to raise of drug resistance. The infection is widespread and intractable. If this happens, more people will be left with an incurable infection which may cause serious health problems. Results: We characterized zoliflodacin thoroughly. Here is discussed the clinical trials and side effects on human health by searching different keywords like “zoliflodacin”, “covid-19”, “clinical trials” from different data sources like Pub-Med, Google-Scholar, and Science-Direct. Zoliflodacin targets antibiotic-resistant N. gonorrhoeae. Zoliflodacin is mainly known based on its therapeutic effects against N. gonorrhoeae. It acts by inhibiting bacterial type 2 topoisomerase with binding site in bacterial gyrase. Zoliflodacin is effective in treating gonococcal urogenital and rectal infection. Conclusion: Antibiotic is the only option to treat N. gonorrhoeae. There is no vaccine available to treat gonorrhea. The new drug, zoliflodacin, specifically targets antibiotic-resistant gonorrhea and its is why researchers have studied this antibiotic from different point of views. In this study, we elaborate the discovery of zoliflodacin, its mechanism of action, the current clinical trials, and the effectiveness of zoliflodacin.
